BioCryst Pharmaceuticals reported $1.96B in Market Capitalization this April of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Alnylam Pharmaceuticals USD 52.54B 7.24B Dec/2025
BioCryst Pharmaceuticals USD 1.66B 64M Dec/2025
Chugai Pharma JPY 13.84T 3.01T Dec/2025
Daiichi Sankyo JPY 6.34T 62.51B Dec/2025
DBV Technologies USD 274M 17M Sep/2025
Enanta Pharmaceuticals USD 122M 98M Dec/2024
Gilead Sciences USD 152.28B 14.55B Dec/2025
GlaxoSmithKline GBP 74.36B 10.31B Dec/2025
Glaxosmithkline GBP 99.93B 13.05B Dec/2025
Incyte USD 19.39B 2.83B Dec/2025
Ionis Pharmaceuticals USD 12.81B 2.39B Dec/2025
Karyopharm Therapeutics USD 652M 517M Apr/2026
Neurocrine Biosciences USD 14.14B 218M Dec/2025
Novavax USD 1.09B 316M Dec/2025
PTC Therapeutics USD 6.1B 1.22B Dec/2025
Regeneron Pharmaceuticals USD 81.12B 21.53B Dec/2025
Roche Holding CHF 266.34B 55.46B Dec/2025
Sarepta Therapeutics USD 2.26B 238M Dec/2025
Ultragenyx Pharmaceutical USD 2.22B 680M Dec/2025
Vertex Pharmaceuticals USD 115.03B 14.61B Dec/2025